Lumakras, Amgen’s groundbreaking KRAS drug, was approved on data from an open-label, single-arm study suggesting, among other things, median progression-free survival of 6.8 months for patients with KRASG12C-mutated non-small cell lung cancer. Now, Amgen says it has the first proof that Lumakras beats chemotherapy — the current standard of care…
…
